Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • CDK
    (17)
  • GSK-3
    (5)
  • Apoptosis
    (4)
  • FAK
    (3)
  • PYK2
    (3)
  • JAK
    (2)
  • MEK
    (2)
  • Aurora Kinase
    (1)
  • DYRK
    (1)
  • Others
    (4)
Filter
Search Result
Results for "

cdk3

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    18
    TargetMol | Inhibitors_Agonists
  • Recombinant Protein
    1
    TargetMol | Recombinant_Protein
  • Antibody Products
    1
    TargetMol | Antibody_Products
NVP-LCQ195
LCQ-195, AT9311
TQ0068902156-99-4In house
NVP-LCQ195 (LCQ-195) (AT9311) is a potent inhibitor of CDK1, CDK2, CDK3 and CDK5 (IC50: 1-42 nM).
  • $40
In Stock
Size
QTY
R547
Ro 4584820
T6312741713-40-6In house
R547 (Ro 4584820) is a potent ATP-competitive inhibitor of CDK1/2/4 with Ki of 2 nM/3 nM/1 nM. It is less potent to CDK7 and GSK3α/β, while inactive to other kinases. Phase 1.
  • $43
In Stock
Size
QTY
(R)-Atuveciclib
BAY-1143572
T104642923012-24-0
(R)-Atuveciclib is an isomer of Atuveciclib. Atuveciclib (BAY 1143572) is a potent and highly selective PTEFb CDK9 inhibitor with an IC50 value of 13 nm for CDK9 CycT1 and a selectivity ratio of 100 for CDK2, with highly bioavailable and orally available advantages.
  • $1,510
10-14 weeks
Size
QTY
Atuveciclib
BAY-1143572 Racemate
T10464L1414943-88-6
Atuveciclib (BAY 1143572) is a potent and highly selective PTEFb CDK9 inhibitor with an IC50 value of 13 nm for CDK9 CycT1 and a selectivity ratio of 100 for CDK2, with highly bioavailable and orally available advantages.
  • $81
In Stock
Size
QTY
TargetMol | Inhibitor Sale
Roniciclib
BAY 1000394
T167841223498-69-8
Roniciclib (BAY 1000394) is a potent pan-CDK inhibitor and a novel oral cytotoxic agent. Roniciclib inhibits the activity of cell-cycle CDKs CDK1, CDK2, CDK3, CDK4, and of transcriptional CDKs CDK7 and CDK9 with IC(50) values in the range between 5 and 25 nmol L.
  • $55
In Stock
Size
QTY
PF-562271 hydrochloride
PF-562271 HCl
T21768939791-41-0
PF-562271 hydrochloride (PF-562271 HCl) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM in cell-free assays, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.
  • $71
In Stock
Size
QTY
RGB-286638 free base
T2378784210-88-4
RGB-286638 free base is a novel CDK inhibitor with IC50s of 1 nM/2 nM/3 nM/4 nM/5 nM for cyclin T1-CDK9/cyclin B1-CDK1/cyclin E-CDK2/cyclin D1-CDK4/cyclin E-CDK3/p35-CDK5 respectively; less potent against cyclin H-CDK7 and cyclin D3-CDK6.
  • $39
In Stock
Size
QTY
PF-562271
PF562271, PF 562271
T2465717907-75-0
PF-562271 is an effective ATP-competitive, reversible inhibitor of FAK(IC50=1.5 nM) and Pyk2 kinase(IC50=13 nM).
  • $54
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
ml167
NCGC00188654, CID44968231
T26701285702-20-6
ML167 (CID44968231) is a highly selective Cdc2-like kinase 4 (Clk4) inhibitor.
  • $29
In Stock
Size
QTY
Ipivivint
T366841481617-15-5
Ipivivint, a first-in-class, orally active and potent CDC-like kinase (CLK) inhibitor, inhibits CLK1 (IC50=1.4 μM), CLK2 (IC50=0.002 μM) and CLK3 (IC50=0.022 μM). Ipivivint reduces Wnt pathway signaling gene expression through inhibiting CLK activity and serine and arginine rich splicing factor (SRSF) phosphorylation and disrupting spliceosome activity. Ipivivint can be used for the research of cancer[1]. Ipivivint (SW480 cells; 0.01~10 μM; 1 hour) potently inhibits SRSF5/6 phosphorylation[1].Ipivivint (SW480 cells; 0.03 μM~3 μM; 48 hour) induced apoptosis[1]..Ipivivint (HEK-293T cells; 0.03 μM~3 μM; 1 hour) inhibits Wnt/β-catenin signaling induced by Wnt3a[1].Ipivivint (SW480 cells; 0.3~10 μM; 6 hour) increases nuclear speckle enlargement[1].Ipivivint (SW480 cells; 0.3~3μM; 24hours) significantly decreases expression of Wnt target genes (AXIN2, LEF1, MYC, and TCF7) and TCF7L2. SM08502 (SW480 cells; 0.03~3μM; 24hours) inhibits cytoplasmic or nuclear fractions protein expression. Ipivivint (NCI-N87 cells) inhibits proliferation[1].Ipivivint strongly inhibits Wnt pathway signaling activity (EC50 = 0.046 μM) in SW480 colon cancer cells[1]. Ipivivint (25 mg/kg; p.o.) potently inhibits tumor SRSF6 phosphorylation[1]. [1]. Tam BY, et al. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models. Cancer Lett. 2020;473:186-197.
  • $1,670
6-8 weeks
Size
QTY
MC180295
(rel)-MC180295
T55332237942-08-2
MC180295 ((rel)-MC180295) is a novel, potent, and highly selective CDK9 inhibitor with an IC50 of 5 nM, demonstrating over 22-fold selectivity compared to other CDKs.
  • $51
In Stock
Size
QTY
JNJ-7706621
JNJ 7706621
T6126443797-96-4
JNJ-7706621 is a potent aurora kinase inhibitor that also inhibits CDK1 and CDK2.
  • $43
In Stock
Size
QTY
TargetMol | Inhibitor Sale
PF-562271 besylate
PF-00562271 Besylate
T6177939791-38-5
PF-562271 besylate (PF-00562271 Besylate) is a potent, ATP-competitive, reversible inhibitor of FAK with IC50 of 1.5 nM, ~10-fold less potent for Pyk2 than FAK and >100-fold selectivity against other protein kinases, except for some CDKs.
  • $32
In Stock
Size
QTY
AT7519
T6205844442-38-2
AT7519 is a CDK1/2/4/6/9 inhibitor (IC50: 10-210 nM). It is less effective to CDK3 and little active to CDK7.
  • $52
In Stock
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
CDK6/PIM1-IN-1
T630712677026-14-9
CDK6/PIM1-IN-1 is a balanced, potent dual inhibitor of CDK6 (IC50: 39 nM) and PIM1 (IC50: 88 nM), also showing inhibitory activity on CDK4 (IC50: 3.6 nM). It significantly inhibits the proliferation of acute myeloid leukemia (AML) cells, arrests the cell cycle in G1 phase, induces cell apoptosis, and demonstrates anti-AML activity.
  • $1,520
6-8 weeks
Size
QTY
cdk7-in-20
T73163
CDK7-IN-20 is a potent, selective, and irreversible inhibitor of Cyclin-Dependent Kinase 7 (CDK7) with an IC50 value of 4 nM, exhibiting over 206-fold selectivity against related kinases [CDK1, CDK2, CDK3, CDK5, CDK6, CDK9, and CDK12]. It holds potential for research into autosomal dominant polycystic kidney disease (ADPKD).
  • $1,520
6-8 weeks
Size
QTY
RGB-286638
T73196784210-87-3
RGB-286638 is a multi-target CDK inhibitor that effectively hampers the kinase activity of a range of cyclin-CDK complexes, including cyclin T1-CDK9 (IC50 = 1 nM), cyclin B1-CDK1 (IC50 = 2 nM), cyclin E-CDK2 (IC50 = 3 nM), cyclin D1-CDK4 (IC50 = 4 nM), cyclin E-CDK3 (IC50 = 5 nM), and p35-CDK5 (IC50 = 5 nM). Additionally, it inhibits other kinases such as GSK-3β (IC50 = 3 nM), TAK1 (IC50 = 5 nM), Jak2 (IC50 = 50 nM), and MEK1 (IC50 = 54 nM), showcasing its versatile inhibitory potential.
  • $766
10-14 weeks
Size
QTY
CDK7-IN-30
T892043040999-70-7
CDK7-IN-30 (Compound 22) is an inhibitor of CDK7 with an IC50 value of 7.21 nM, effectively inhibiting the phosphorylation of RNA polymerase II and CDK2. It can induce cell apoptosis (apoptosis) and exhibits anticancer activity, making it useful for cancer research.
  • $1,520
4-6 weeks
Size
QTY